Silo Pharma Q2 FY26 net loss narrows 30.8% to $832,829

SILO•2026-08-13

Silo Pharma posted a net loss of $832,829 in the quarter ended June 30, narrowing 30.8% from a year earlier.
Revenue was nil, versus $18,025 a year earlier, as it stopped recognizing license and sublicense fee revenue after April 1.
Operating loss narrowed 25.6% to $928,949 as operating expenses fell 26.6% to $928,949.
Research and development expense dropped 58.4% to $298,418 on lower costs tied to investigator-sponsored studies and other projects.
Liquidity totaled $3.28 million in cash and $1.95 million in short-term investments at June 30; a July 9 private placement netted $3.53 million.

Sources

Sec